Poolbeg Pharma A.I. Unlocking the power of unique human challenge trial data

Poolbeg Pharma A.I. Unlocking the power of unique human challenge trial data
[shareaholic app="share_buttons" id_name="post_below_content"]

Poolbeg Pharma (LON:POLB) Chief Executive Officer Jeremy Skillington talks us through the Poolbeg September 2023 company presentation.

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), is a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
Poolbeg Pharma unveils promising POLB 001 data at ASH Meeting, highlighting its potential as a CRS preventative therapy in cancer immunotherapies.
Poolbeg Pharma secures US patent approval for POLB 001, enhancing its IP portfolio and advancing treatments for severe influenza and cytokine storms.
Poolbeg Pharma to showcase POLB 001's promising results in reducing CRS at ASH 2024, highlighting breakthroughs in cancer immunotherapy safety.
Discover six high-growth AIM-listed British companies delivering exceptional returns, with share prices surging up to 150% in the past year.

Search

Search